object
human
bocaviru
hbov
recent
discov
parvoviru
associ
acut
respiratori
tract
infect
children
object
present
studi
determin
frequenc
clinic
relev
hbov
infect
adult
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
method
retrospect
test
copd
patient
aecopd
stabl
diseas
nasal
lavag
induc
sputum
obtain
presenc
hbov
deoxyribonucl
acid
dna
specifi
citi
posit
polymeras
chain
reaction
result
confi
rmed
sequenc
result
two
hundr
two
patient
pcr
result
avail
nasal
lavag
induc
sputum
sampl
elig
data
analysi
hbov
dna
detect
three
patient
one
patient
aecopd
thu
frequenc
hbov
infect
demonstr
low
aecopd
stabl
copd
hbov
found
two
sputum
one
nasal
lavag
sampl
differ
patient
respect
sequenc
reveal
sequenc
ident
refer
strain
conclus
hbov
detect
infrequ
sinc
detect
hbov
upper
lower
respiratori
tract
specimen
aecopd
well
stabl
diseas
major
role
hbov
infect
adult
aecopd
unlik
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
account
signifi
cant
number
hospit
therefor
present
import
econom
burden
health
care
aecopd
substanti
contribut
loss
lung
function
diseas
progress
mortal
patient
present
aecopd
describ
symptom
respiratori
infect
histor
bacteria
consid
major
caus
infecti
exacerb
bacteria
also
found
clinic
stabl
patient
role
bacteri
infect
remain
controversi
broad
avail
molecular
diagnost
like
polymeras
chain
reaction
pcr
promin
contribut
common
viral
agent
upper
respiratori
tract
infect
like
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
etiolog
aecopd
increasingli
recogn
nevertheless
one
third
sever
exacerb
caus
remain
unknown
recent
year
novel
respiratori
virus
includ
human
metapneumoviru
hmpv
sever
coronavirus
sar
discov
role
aecopd
alreadi
defi
ned
extent
ringshausen
et
al
human
bocaviru
hbov
novel
parvoviru
initi
discov
respiratori
secret
swedish
children
symptom
upper
lower
respiratori
tract
infect
frequenc
prove
role
caus
agent
acut
respiratori
tract
infect
challeng
hbov
propag
cell
cultur
anim
model
yet
establish
henc
modifi
ed
postul
koch
applic
numer
retrospect
prospect
studi
suggest
associ
hbov
acut
respiratori
tract
infect
children
clinic
fi
nding
consist
wheez
episod
asthma
exacerb
acut
obstruct
bronchiti
bronchiol
croup
pneumonia
infant
age
two
year
patient
structur
pulmonari
diseas
immun
disord
seem
predominantli
affect
preliminari
evid
provid
acut
hbov
infect
may
take
virem
cours
may
also
capabl
persist
respiratori
tract
hbov
infect
appear
endem
worldwid
first
studi
seroepidemiolog
give
evid
protect
matern
antibodi
within
fi
rst
month
life
japanes
studi
children
examin
immunoglobulin
g
antibodi
viral
protein
age
year
emphas
ubiquit
natur
taken
togeth
fi
nding
suggest
protect
immun
past
infect
may
explain
hbov
compar
rare
adult
frequenc
hbov
detect
respiratori
specimen
children
describ
literatur
vari
recent
hbov
detect
rate
describ
among
german
children
symptom
respiratori
tract
infect
knowledg
role
hbov
well
character
popul
adult
patient
aecopd
systemat
studi
yet
implic
frequent
detect
aecopd
introduct
clinic
routin
test
subsequ
decreas
antimicrobi
overus
aim
present
studi
determin
preval
hbov
infect
hospit
patient
aecopd
establish
potenti
clinic
relev
comparison
patient
stabl
copd
hospit
reason
acut
exacerb
retrospect
test
two
group
copd
patient
presenc
hbov
deoxyribonucl
acid
dna
patient
aecopd
control
group
copd
patient
stabl
diseas
select
evalu
subject
enrol
octob
april
prospect
casecontrol
manner
ratio
order
prevent
season
select
bia
subject
recruit
ratio
month
inclus
criteria
group
age
year
exacerb
stabl
copd
chronic
airfl
ow
limit
forc
expiratori
volum
one
second
fev
predict
admiss
hospit
written
inform
consent
exclus
criteria
group
bronchial
asthma
dyspnea
origin
pneumonia
tuberculosi
pulmonari
fi
brosi
bronchiectasi
lung
cancer
congest
heart
failur
collect
demograph
clinic
data
standard
collect
process
nasal
lavag
induc
sputum
sampl
assess
lung
function
evalu
chest
radiograph
underli
common
defi
nition
describ
detail
briefl
copd
aecopd
defi
ned
global
initi
chronic
obstruct
lung
diseas
gold
aecopd
character
worsen
dyspnea
cough
andor
sputum
expector
beyond
normal
daytoday
variat
acut
onset
patient
stabl
copd
experi
exacerb
within
last
day
prior
hospit
admiss
chang
inhal
oral
medic
within
last
day
admit
condit
medic
depart
pulmonari
care
follow
variabl
select
data
analysi
age
gender
bodi
mass
index
smoke
behavior
smoke
histori
pack
year
oral
inhal
steroid
medic
admiss
dose
oral
steroid
medic
applic
creactiv
protein
white
blood
count
valu
clinic
symptom
admiss
comorbid
copd
statu
spirometr
data
assess
admiss
group
discharg
patient
aecopd
fev
liter
predict
forc
vital
capac
fvc
liter
predict
fev
fvc
nasal
lavag
induc
sputum
sampl
obtain
patient
store
dna
extract
perform
viral
coinfect
common
respiratori
virus
hmpv
hrv
infl
uenza
virus
b
parainfl
uenza
viru
rsv
determin
sensit
realtim
pcr
assay
patient
nasal
lavag
induc
sputum
sampl
previous
publish
hbov
pcr
sequenc
dna
extract
induc
sputum
nasal
lavag
sampl
use
qiaamp
dna
blood
mini
kit
qiagen
hilden
germani
accord
instruct
manufactur
elut
volum
extract
dna
sampl
store
analysi
hbov
dna
amplifi
cation
perform
nonstructur
protein
primer
describ
alland
colleagu
use
hotstartaq
dna
polymeras
qiagen
hilden
germani
pcr
reaction
carri
volum
consist
extract
dna
qiagen
hotstar
buffer
dntp
fi
nal
concentr
pmol
primer
u
taq
polymeras
previous
describ
weissbrich
colleagu
cycl
condit
cycl
min
preheat
step
min
pcr
product
visual
stain
ethidium
bromid
agaros
gel
electrophoresi
consid
posit
pcr
reaction
band
expect
size
base
pair
bp
detect
sequenc
specifi
citi
confi
rmed
sequenc
posit
pcr
product
direct
use
big
dye
termin
chemistri
abi
prism
appli
biosystem
darmstadt
germani
laboratori
team
blind
patient
copd
statu
strict
laboratori
procedur
implement
prevent
pcr
contamin
one
neg
control
amplifi
ed
everi
fi
sampl
plasmid
contain
bp
hbov
dna
isol
stockholm
genbank
clone
vector
invitrogen
paisley
uk
use
posit
control
sensit
hbov
pcr
assay
assess
dilut
seri
determin
singl
copi
viral
genom
per
reaction
data
analysi
perform
use
spss
version
spss
inc
chicago
il
usa
categor
data
compar
pearson
chisquar
fisher
exact
test
appropri
normal
distribut
continu
variabl
determin
kolmogorovsmirnov
test
differ
subsequ
determin
either
student
ttest
mannwhitney
u
test
p
valu
report
calcul
twosid
statist
signifi
canc
set
p
studi
protocol
approv
ethic
committe
ruhr
univers
bochum
germani
studi
particip
gave
written
inform
consent
prior
studi
inclus
octob
april
induc
sputum
nasal
lavag
sampl
hospit
copd
patient
acut
exacerb
stabl
diseas
obtain
casecontrol
setup
ratio
pcr
result
presenc
hbov
dna
avail
induc
sputum
nasal
lavag
specimen
patient
acut
exacerb
stabl
diseas
constitut
actual
studi
popul
figur
ten
subject
exclud
data
analysi
two
induc
sputum
eight
nasal
lavag
sampl
suffi
cient
pcr
experi
demograph
clinic
featur
studi
popul
shown
tabl
two
group
compar
term
age
sex
bodi
mass
index
smoke
behavior
pack
year
frequenc
inhal
oral
steroid
medic
age
distribut
aecopd
group
rang
year
control
group
signifi
cant
differ
appar
increas
airfl
ow
limit
admiss
fev
liter
predict
higher
infl
ammatori
laboratori
paramet
indic
infect
crp
leukocyt
higher
dose
administ
oral
steroid
admiss
aecopd
group
spirometr
data
discharg
avail
patient
aecopd
signifi
cantli
improv
treatment
acut
exacerb
compar
baselin
airfl
ow
control
group
tabl
three
patient
test
hbov
dna
found
posit
pcr
subsequ
sequenc
subject
one
acut
exacerb
two
stabl
sever
copd
tabl
thu
frequenc
hbov
detect
demonstr
low
aecopd
stabl
copd
two
patient
hbov
detect
induc
sputum
sampl
wherea
one
nasal
lavag
sampl
test
posit
hbov
abbrevi
ae
copd
acut
exacerb
chronic
obstruct
pulmonari
diseas
crp
creactiv
protein
fev
forc
expiratori
volum
one
second
admiss
fev
baselin
forc
expiratori
volum
one
second
control
group
discharg
recoveri
exacerb
aecopd
group
sd
standard
deviat
clinic
featur
three
patient
posit
hbov
shown
tabl
hbov
found
two
sputum
sampl
one
nasal
lavag
sampl
correspond
nasal
lavag
sputum
sampl
neg
respect
patient
male
present
winter
spring
season
march
novemb
januari
show
infi
ltration
chest
xray
moder
sever
impair
lung
function
accord
gold
stage
iiiv
report
variou
comorbid
arteri
hypertens
cor
pulmonal
obstruct
sleep
apnea
cardiomyopathi
ischem
stroke
two
subject
stabl
copd
report
cough
whitish
expector
dyspnea
exert
without
recent
chang
sever
individu
aecopd
complain
progress
cough
purul
expector
well
dyspnea
rest
symptom
acut
gastroenter
two
patient
gold
stage
ii
iii
experienc
aecopd
within
last
month
preced
studi
inclus
patient
stabl
copd
gold
stage
iv
report
three
exacerb
per
year
sputum
microbiolog
steril
two
subject
candida
albican
detect
subject
viral
coinfect
rsv
viral
copi
detect
induc
sputum
aecopd
patient
rsv
infl
uenza
viru
viral
copi
respect
detect
nasal
lavag
sampl
exist
two
three
patient
sequenc
determin
three
posit
hbov
pcr
product
reveal
sequenc
ident
swedish
strain
nucleotid
sequenc
obtain
year
nucleotid
sequenc
amplifi
ed
pcr
product
deposit
genbank
result
studi
genbank
retrospect
studi
prospect
recruit
casecontrol
cohort
found
hbov
detect
infrequ
adult
hospit
patient
acut
exacerb
stabl
copd
year
urban
region
central
ruhr
area
germani
total
hbov
dna
detect
three
patient
found
acut
exacerb
stabl
diseas
well
induc
sputum
nasal
lavag
sampl
fi
nding
suggest
hbov
may
clinic
relev
adult
patient
aecopd
routin
test
hbov
popul
may
warrant
data
hbov
infect
adult
limit
screen
respiratori
virus
gener
recommend
adult
symptom
lower
respiratori
tract
infect
thu
materi
largescal
retrospect
analysi
hardli
avail
low
frequenc
overal
hbov
detect
found
studi
agreement
studi
adult
initi
investig
alland
colleagu
detect
hbov
adult
respiratori
symptom
larg
thai
studi
detect
hbov
subject
age
year
older
includ
control
two
italian
studi
found
frequenc
year
adult
patient
despit
use
differ
pcr
assay
realtim
singleround
pcr
respect
notabl
recent
usamerican
studi
found
ident
frequenc
adult
previou
studi
explicitli
includ
patient
aecopd
found
hbov
one
adult
patient
aecopd
pneumonia
canadian
male
receiv
oral
steroid
treatment
exacerb
unfortun
report
cover
one
winter
season
neither
specifi
ed
proport
aecopd
patient
includ
provid
clinic
detail
popul
contrast
report
mention
predominantli
studi
specimen
repres
upper
respiratori
tract
nasal
swab
nasopharyng
aspir
studi
investig
induc
sputum
nasal
lavag
sampl
previou
pcrbase
studi
demonstr
aecopd
requir
hospit
admiss
significantli
associ
presenc
common
respiratori
virus
induc
sputum
may
reliabl
refl
ect
lower
respiratori
tract
higher
viral
yield
upper
respiratori
tract
specimen
patient
aecopd
hrv
infl
uenza
viru
rsv
frequent
detect
similar
studi
recent
found
anoth
emerg
respiratori
viru
hmpv
infrequ
aecopd
well
overal
preval
howev
three
hmpv
detect
occur
aecopd
group
make
asymptomat
carriag
unlik
present
studi
investig
frequenc
hbov
infect
four
consecut
year
special
care
avoid
season
select
bia
monthli
recruit
group
casecontrol
setup
use
optim
hbov
pcr
assay
perform
cycl
singleround
hotstart
pcr
sensit
enough
detect
singl
hbov
dna
copi
per
reaction
sequenc
pcr
product
reveal
nucleotid
ident
differ
sampl
year
fi
nding
limit
genet
variat
agreement
previou
report
present
studi
viral
coinfect
assess
sensit
pcr
assay
exist
two
three
hbovposit
subject
although
specimen
evalu
presenc
less
common
respiratori
virus
like
adenoviru
coronavirus
parainfl
uenza
virus
fi
nding
consist
hypothesi
hbov
carri
low
copi
number
individu
detect
enhanc
viru
reactiv
anoth
respiratori
infect
due
low
detect
rate
studi
analysi
potenti
associ
hbov
infect
distinct
clinic
featur
possibl
remark
patient
aecopd
test
posit
hbov
suffer
concomit
acut
gastroenter
hbov
also
propos
caus
pathogen
acut
gastroenter
far
etiolog
role
remain
controversi
conclus
fi
rst
control
studi
preval
hbov
adult
hospit
patient
aecopd
found
hbov
low
frequenc
patient
acut
exacerb
well
stabl
copd
compar
report
adult
studi
popul
thu
major
role
hbov
infect
common
trigger
aecopd
unlik
fcr
conceiv
design
studi
perform
statist
analysi
interpret
data
supervis
studi
draft
manuscript
ayt
conduct
pcr
experi
contribut
data
analysi
revis
manuscript
critic
import
intellectu
content
ta
involv
establish
pcr
assay
construct
plasmid
posit
control
revis
manuscript
critic
import
intellectu
content
ib
involv
process
specimen
ua
jk
bmh
recruit
patient
revis
manuscript
critic
import
intellectu
content
gsw
contribut
studi
design
supervis
studi
gr
contribut
studi
design
analysi
interpret
data
supervis
studi
revis
manuscript
critic
import
intellectu
content
author
read
approv
fi
nal
manuscript
